Please note: This meeting is taking place in-person only at the Embassy Suites By Hilton - New Orleans Convention Centre,

and online attendance will not be available.

Conference Agenda

Friday – April 8, 2022

9:00 am In-Person Registration Opens

9:50 am Hanson Wade Opening Remarks

9:55 am Chair’s Opening Remarks

Expanding the True Value of Multiplex Immunofluorescence with Clinical Utility in Mind

10:00 am Challenges in Triple Negative breast cancer (TNBC)

Synopsis

• Learning that TNBC is a challenge in breast cancer diagnosis and treatment
• Understanding that TNBC is a heterogenous disease
• Exploring how spatial biology can help better understand and solve current problems diagnosing and treating TNBC

10:40 am Spatial Transcriptomics in The Era of Immunotherapy

  • Arutha Kulasinghe Clinical-oMx Lab Head, University of Queensland Diamantina Institute

Synopsis

• Spatial genomics for the immuno-oncology space to Spatial genomics in the immuno-oncology field
• Applications of spatial profiling of the tumour microenvironment in lung, head, neck and skin cancer
• The development of gene signatures of response to therapy

11:00 am Characterization of Immune Excluded Tumors by Multiplex Immunofluorescence for Precision Oncology applications

  • Laura Dillon Head of Translational Biomarkers, Parthenon Therapeutics

Synopsis

• Understanding how the spatial relationship between immune cells and the tumor epithelium vs tumor associated stroma is key to reviewing immune exclusion and its relationship to CPI therapy resistance
• Thoughtful mIF panel design and reagent validation are necessary to enable interpretation of mIF output
• Novel methods are needed to better characterize the extracellular matrix from WSIs

11:20 am Morning Break

11:50 am Panel Discussion: Multiplex IF Panel Design & the Value of Transcriptomics & Protein Detection

Synopsis

• Overcoming key barriers to large-scale adoption and application of multiplexed immunofluorescence in clinical settings, can we ever overcome the use of just PD1/PDL1 assays?
• How can multiplex immunofluorescence improve validation of biomarkers in tissue when evaluating clinical utility of compounds of interest?
• Evaluating the reliability of biomarker results across technology types and approaching multi-OMICs datasets
• Discussing the impact of preanalytical variables on biomarker staining

12:50 pm Lunch Break

Uncovering the Potential of Image Analysis to Enhance Patient Care

1:50 pm Considerations for Reproducible Quantitative Image Analysis & AI Algorithms: A Pathologist’s Perspective

  • Marilyn Bui Professor & Senior Member, Scientific Director of Analytic Microscopy Core, Director of Cytopathology Fellowship, Moffit Cancer Center

Synopsis

• Discovering the importance of quality image, quality imaging analysis tool and quality collaboration with pathologists and how
they are the three pillars of impactful tissue-based biomarker discovery

2:30 pm Dissecting Spatial & Functional Features of Tumor Immune Microenvironment Linked to Immune Checkpoint Inhibitor (ICI) in Solid Tumor

  • Tae-Hyun Hwang Florida Department of Health Cancer Chair, Department of AI & Informatics & Immunology, Mayo Clinic

Synopsis

• Discussing spatial transcriptome, tumor immune microenvironment and cell-cell interactions
• Uncovering why interactions of the tumor with immune and stromal cells in the immune microenvironment need to be considered to enhance biomarker discovery and therapeutic strategies to improve ICI efficacy

2:50 pm From Colourful to Meaningful – Empowering Translational Science with mIF Image Data Analysis

  • Florian Leiss Vice President of Digital Health Strategies, Ultivue

Synopsis

• Advancing translational science with mIF requires the staining of tissue section, image analysis and data mining of readouts in concert. Focusing on any one of these steps alone is going to fall short
• Multiple assays are often required during different phases of a biomarker development program and across multiple related studies, and image analysis approaches should also differ depending on the stage in biomarker development
• Optimizing transition between assays and stages of biomarker development is as important as optimizing performance at each step

3:10 pm Afternoon Break & Networking

3:40 pm Clinical-Grade Computational Pathology & its Impact on Cancer Care

Synopsis

• Understand the impact of AI on clinical practice in pathology
• Illustrate the difficulties of training an AI in pathology
• Learn to differentiate between hype and real-world evidence in AI

4:00 pm Panel Discussion: Improving Spatial Profiling with Novel AI Tools & Algorithms

  • Florian Leiss Vice President of Digital Health Strategies, Ultivue
  • Tae-Hyun Hwang Florida Department of Health Cancer Chair, Department of AI & Informatics & Immunology, Mayo Clinic
  • Alexander Lazar Professor, Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center
  • Michael Surace Associate Director, AstraZeneca
  • James Mansfield Senior Vice President, Research Business Development, Visiopharm
  • Adam Smith Vice President, Life Science Sales & Applications, Indica Labs

Synopsis

• How can we increase the reliability and consistency of automated IA tools?
• How can novel IA tools and AI combine benefits of molecular approaches with information from tissue morphology?
• How can we ensure the development of an accurate and consistent immune cell profiling algorithm for specific tumor indications?

4:45 pm The Role of AI-Powered Digital Pathology for Analyzing mIF Assays & Understanding the Spatial Architecture of Cells & their Surroundings

Synopsis

• A new platform for providing a rich user experience to visualize imaging results
• Case studies which unveil the value of AI-powered digital pathology in mIF and spatial analysis
• Training H&E-based cell detection models using semi-automatically generated labels from mIF stained tissue

5:05 pm Chair’s Closing Remarks

5:15 pm Hanson Wade Closing Remarks

5:30 pm End of 2nd Biomarker Insights Summit